United States Continuous Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Continuous Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence and Earlier Diagnoses

CDC surveillance shows adult diabetes prevalence rising from 9.7% in 1999-2000 to 15.8% in 2021-2023, translating to 38.4 million Americans who potentially benefit from continuous glucose monitoring market solutions. Younger adults are being screened sooner, which pushes CGM adoption earlier in the disease course. Payers increasingly view CGM as a frontline therapy that prevents severe hypoglycemia and costly hospitalizations, making reimbursement justification easier. Providers treat CGM as a foundational self-management tool rather than an advanced add-on, a perception shift that enlarges the addressable base. As a result, the continuous glucose monitoring market gains sustained volume tailwinds from both Type-1 and Type-2 cohorts, whose treatment plans now anchor around real-time data feedback.

Medicare/Medicaid Expansion for Type-2 Basal-Only Patients

In April 2023, CMS broadened coverage to include Type-2 patients using basal insulin only, opening CGM eligibility to an extra 1.5 million beneficiaries. Adoption momentum varies by state Medicaid policy, yet progressive states already report higher authorization rates that speed volume uptake. The policy decision rests on evidence that CGM reduces emergency visits and inpatient costs, benefits that resonate with value-based care contracts. Pharmacy benefit pathways continue to evolve, so manufacturers are expanding distribution channels and patient support programs to navigate differing durable-equipment billing rules. The net effect is a medium-term surge in unit sales as both public and commercial payers harmonize benefit designs.

Sensor Price Erosion Below USD 60 per 14-Day Wear Period

Dexcom’s Stelo debut at USD 89-99 and Abbott’s similar OTC strategies indicate a broader slide toward sub-USD 60 sensor pricing over the next two years. Manufacturing automation, longer wear times, and simplified calibration have trimmed unit costs, allowing lower retail prices without eroding gross margins as steeply as feared. Affordable cash-pay options widen access for under-insured patients who previously rationed self-monitoring supplies. As prices fall, manufacturers pivot toward volume-based recurring revenue, favoring firms that already produce more than 10 million sensors annually. These economics could raise the entry barrier for smaller challengers, thereby reinforcing the high-volume leadership positions inside the continuous glucose monitoring market.

Shift to OTC Wellness CGMs Expands Addressable Base

The FDA cleared Dexcom’s Stelo as the first over-the-counter CGM in March 2024^{[1]U.S. Food and Drug Administration, “FDA Clears First Over-the-Counter Continuous Glucose Monitor,” fda.gov}. Without prescription hurdles, marketing now targets health-conscious consumers who seek metabolic insight rather than strict diabetes control. Usage patterns differ; wellness buyers may use CGMs episodically alongside diet or fitness regimens, setting up demand spikes around seasonal initiatives like New Year resolutions. To cultivate recurring revenue, vendors bundle data analytics and lifestyle coaching subscriptions that deepen engagement beyond sensor hardware. Success in this arena could double the continuous glucose monitoring market’s reachable population by 2030.

GLP-1 Induced Glucose Normalization Reduces CGM Starts

Rapid uptake of GLP-1 receptor agonists such as semaglutide brings many patients to normalized HbA1c levels, lowering perceived need for continuous monitoring. Studies show approximately 46% of non-diabetic users discontinue GLP-1 within a year, causing unpredictable sensor demand^{[2]Patricia J. Rodriguez et al., “Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults,” medrxiv.org}. Early discontinuation produces gaps in monitoring continuity, making it difficult for providers to justify CGM prescriptions. Nonetheless, emerging evidence supports CGM use during dose titration and to catch hypoglycemia in aggressively treated cohorts. Manufacturers now educate clinicians on complementary roles for CGM even when pharmacotherapy remains effective, which may soften this negative impact over time.

Patch-Pump and CGM Bundles Limit Stand-Alone Sensor Sales

Automated insulin delivery systems increasingly bundle proprietary sensors with pumps, locking users into specific ecosystems. Tandem’s Control-IQ platform requires Dexcom G6 sensors, and Abbott has exclusive supply deals with several pump makers. These arrangements create predictable high-margin revenue for participants yet reduce open-market sensor volumes. Closed-loop systems represent a large number of pump users today and grow 15-20% each year. If bundling becomes the norm, smaller or sensor-only companies may find access to the continuous glucose monitoring market more constrained, pushing them toward niche or wellness segments.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Sensors Anchor Recurring Revenue Streams

Sensors captured 87.32% of the continuous glucose monitoring market in 2025 and are forecast to compound at an 18.05% rate through 2031. This dominance stems from 14- to 15-day replacement cycles that create subscription-like revenue predictability. The continuous glucose monitoring market size for sensor hardware is on track to surpass USD 14.2 billion by 2031, underpinned by mass-production cost advantages and AI-ready data output. Dexcom’s G7 15-day sensor, cleared in April 2025, sustains 8.0% MARD accuracy, demonstrating how incremental performance gains support premium price points. Longer wear times and Bluetooth direct-to-phone links minimize the role of dedicated receivers, paving the way for consumer-scale adoption well beyond diabetes.

Durable components—receivers and transmitters—hold 12.68% share and grow at just 19.35% through the forecast. Their decelerating curve reflects smartphone ubiquity that makes proprietary displays obsolete. Transmitters lasting 90-180 days dampen replacement frequency, and regulatory scrutiny pushes manufacturers to extend life cycles further. Higher per-unit prices cushion revenue, yet overall share slips as sensors absorb much of the system’s value. Competitive focus, therefore, centers on transmitter miniaturization and waterproofing to simplify closed-loop pump pairing.

By End User: Home-Based Management Leads Adoption

Home and personal users represent 67.10% of the continuous glucose monitoring market share in 2025, a figure projected to climb with an 17.62% CAGR as self-management becomes standard care. COVID-19 accelerated remote monitoring norms, and these behaviors persist because patients value autonomy. Pharmacy benefit coverage and direct-ship logistics cut clinic dependency, while mobile apps translate glucose patterns into actionable guidance. Health coaches and telehealth consults reinforce proper usage, embedding CGM into everyday routines.

Hospitals and clinics account for 32.90% of 2025 revenue yet rise at a faster 19.01% CAGR from a smaller base. Value-based purchasing encourages inpatient systems to swap point-of-care finger sticks for continuous tracking, particularly on surgical floors and high-risk medical units. Integration with electronic medical records is improving, reducing nursing workload while elevating patient safety. Over time, many admitted patients already wearing CGM at home will stay on their own devices during hospitalization, bridging both end-user categories and deepening market entrenchment.

By Demography: Pediatric Uptake Surges on Early Intervention

Adults held the majority, 60.88% share of the continuous glucose monitoring market size in 2025, supported by Medicare expansions and employer wellness programs. Yet adoption rates vary within this age range. Younger adults under 50 embrace device ecosystems quickly, while older cohorts face smartphone literacy and cost hurdles even after coverage reforms. Education campaigns that pair CGM data with nutrition counseling show promise in improving long-term adherence.

The pediatric population, still smaller in absolute terms, grows fastest at 19.12% CAGR. Early use prevents long-term complications, making payers willing to absorb sensor costs. School nurses increasingly manage CGM alerts during class, an operational change that removes a prior barrier to classroom participation. Parents also leverage cloud portals to monitor children remotely, reducing fear of nocturnal hypoglycemia and driving strong word-of-mouth advocacy that furthers adoption.

Geography Analysis

The United States' continuous glucose monitoring market shows notable regional clusters. Medicare Advantage penetration above 40% in these areas provides richer benefits that quicken uptake. By contrast, Medicaid policies range widely; Washington state covers CGM broadly, while several Midwestern states still require prior authorizations that impede installation.

California stands out because both Dexcom and Abbott operate sizable development hubs there. Early employee trials often precede formal FDA submissions, seeding local physician familiarity. Meanwhile, employer-sponsored wellness plans in Silicon Valley offer CGM stipends that illustrate broader consumer possibilities. International sales success of U.S. brands feeds domestic R&D budgets, with European FreeStyle Libre volumes helping Abbott price competitively at home. Balancing foreign expansion and domestic defense remains a strategic tightrope for all major manufacturers.

Regulatory Landscape

In the United States, continuous glucose monitoring (CGM) systems are regulated by the US Food and Drug Administration (FDA) as medical devices, including the integrated CGM classification under 21 CFR 862.1355. FDA clearance activity continues to affect competitive timelines, including 510(k) clearance for Dexcom G7 15-day (K253737) in February 2026, and software-related post-market actions such as the April 2026 Class 2 recall for the Dexcom ONE+ and G7 iOS apps tied to a display issue. Alongside device authorizations, FDA issued final guidance in May 2026 on submitting CGM data in clinical trials to support marketing applications for drugs and biologics, reinforcing expectations for CGM data as these sensors are used as endpoints and safety inputs in broader therapeutic programs.

Coverage policy is a central demand enabler. CMS maintains national and local coverage pathways under Medicare Part B, including criteria for CGM access for insulin-treated beneficiaries and those with problematic hypoglycemia, alongside LCDs such as L38662 (effective October 2025) addressing implantable CGMs and related coverage requirements. These coverage rules feed into durable medical equipment and pharmacy benefit workflows, shaping documentation burden and authorization speed for home and personal use, as well as for hospital and clinic adoption.

Market Opportunities and Future Outlook

Coverage expansion and benefit design simplification are practical whitespace levers in the United States CGM market, especially for people with type 2 diabetes and for users managed outside intensive insulin regimens. Under CMS Part B coverage, CGM eligibility extends to insulin-treated patients and those with a history of problematic hypoglycemia, while state-level Medicaid variability continues to create access gaps that manufacturers and channel partners can address through payer contracting, documentation tools, and pharmacy benefit distribution. OTC CGM availability also expands the addressable base beyond traditional endocrinology prescribing, supporting service models that pair episodic sensor use with coaching and digital interpretation for non-insulin and wellness consumers.

Product and ecosystem differentiation also creates opportunity areas where clinical risk is not fully captured by glucose-only sensing or where wear-time and interoperability are decisive. Abbott and Medtronic have publicly advanced dual glucose-ketone sensing initiatives, and Senseonics has positioned Eversense 365 commercialization alongside pipeline programs (including Gemini and Freedom) and efforts to expand compatibility with automated insulin delivery systems. These efforts support whitespace in higher-acuity management, such as ketone monitoring to help manage ketoacidosis risk, and in longer-wear implantable formats. They also raise the importance of software reliability and data integration as CGM becomes embedded in routine care pathways and connected therapy stacks.